{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-169038","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.559901+00:00","generated_at":"2026-06-13T22:41:34.507635+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viridian shareholders approve 2M share increase to 2016 Equity Plan at annual meeting","bullets":["Stockholders approved amendment to 2016 Equity Incentive Plan, increasing share reserve by 2,000,000 shares.","Elected Tomas Kiselak and Jennifer K. Moses as Class II directors to serve until 2026.","Ratified KPMG as independent auditor for 2023 with 39,588,463 votes for.","Advisory vote on NEO compensation passed with 22,946,964 for and 12,351,317 against.","Total shares outstanding as of record date: 43,108,897."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-169038","json":"https://secwatch.observer/filing/0001193125-23-169038.json","markdown":"https://secwatch.observer/filing/0001193125-23-169038.md","text":"https://secwatch.observer/filing/0001193125-23-169038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/d521711d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:41:34.507635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30567c4f8e204f1b4681e5ea7390a9611e2edc1d","claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders.","evidence_excerpt":"1. Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 26,435,249 8,884,876 4,287,967 Jennifer K. Moses 34,979,960 340,165 4,287,967","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"4e6c6ada4e2057e2abf82dd03d5cabc1f0271cf4","claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder.","evidence_excerpt":"4. Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder: For Against Abstentions Broker Non-Votes 22,896,437 12,404,022 19,666 4,287,967","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"cd2c280fd8c3bd3a315a428e9fb061aade898b58","claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023.","evidence_excerpt":"2. Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023: For Against Abstentions Broker Non-Votes 39,588,463 9,049 10,580 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"f634b7cd5acdd2ffeaad628909b2c818d2ce12d6","claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers.","evidence_excerpt":"3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 22,946,964 12,351,317 21,844 4,287,967","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}